- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07529808
Étude de phase 1/2 du BHB810 dans l'adénocarcinome gastrique avancé et de la jonction œsogastrique
Phase 1/2, ouverte, multicentrique, d'escalade de dose et d'expansion de l'étude du BHB810 chez des participants atteints d'adénocarcinome gastrique avancé et de la jonction gastro-œsophagienne
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.
Aperçu de l'étude
Statut
Les conditions
- Cancer de l'estomac
- Cancer du pancréas
- Adénocarcinome gastrique
- Adénocarcinome gastro-oesophagien
- Cancer gastrique avancé
- Cancer colorectal (côlon ou rectal)
- Cancers gastro-intestinaux
- Cancer gastrique (estomac)
- Cancer gastro-intestinal métastatique
- Adénocarcinome de la jonction gastro-oesophagienne (JGE)
- Cancer gastro-oesophagien (GC)
- Cancer de la jonction gastro-oesophagienne (JGE)
- Adénocarcinome gastro-intestinal
- Tumeurs solides avancées CDH17 positives
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope Duarte
-
Chercheur principal:
- Dani Castillo, MD
-
Contact:
- Jalene Tangen
- Numéro de téléphone: 833-917-5715
- E-mail: jtangen@coh.org
-
Santa Monica, California, États-Unis, 90404
- Pas encore de recrutement
- University of California at Los Angeles
-
Chercheur principal:
- Zev Wainberg, MD
-
Contact:
- Rachel Andes
- Numéro de téléphone: 16122 310-633-8400
- E-mail: randes@mednet.ucla.edu
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- NEXT Virginia
-
Chercheur principal:
- Alexander Spira, MD
-
Contact:
- Maybelle De La Rosa
- Numéro de téléphone: 703-783-4518
- E-mail: mdelarosa@nextoncology.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
-
Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.
- Participants in Phase 1 Backfill Cohorts & Phase 2 must be CDH17-positive by central testing.
- Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
-
At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
-
Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
-
Adequate organ and marrow function as defined in the protocol
Exclusion Criteria:
-
Prior cancer treatment as follows, relative to the first planned dose of trial intervention:
- Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
- Monoclonal antibody-based therapy (including ADCs) within 4 weeks
- Immune checkpoint inhibitors within 4 weeks
- Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
-
Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
-
Known hypersensitivity or allergic reaction to BHB810 or it's excipients
-
Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV
-
QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
-
Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
-
Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
-
Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
-
Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose Escalation and Backfill Cohorts
Dose escalation and backfill cohorts |
Every 2 weeks IV administration |
|
Expérimental: Recommended Phase 2 Dose Level 1 (RP2D1)
Dose level 1 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
|
Expérimental: Recommended Phase 2 Dose Level 2 (RP2D2)
Dose level 2 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)
Délai: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by evaluation of AEs, SAEs, DLTs, and clinically significant changes safety assessments, like lab tests, vital signs, and other safety assessments Phase 1 (Dose Escalation & Backfill Cohorts) and Phase 2 (Dose Optimization) DLTs apply to Phase 1 Dose Escalation Cohorts only. |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Incidence of participants who have a dose modification of BHB810 due to toxicity
Délai: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by assessment of dose modifications due to toxicity Phase 1 (Dose Escalation & Backfill Cohorts) |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Overall Response Rate (ORR)
Délai: Screening through End of Treatment, an average of 6 months
|
Identify the recommended Phase 2 dose (RP2D) by comparing 2 doses of BHB810 by evaluating the ORR of participants according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical Benefit Rate (CBR)
Délai: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Number of participants who achieve stable disease (SD) for at least 6 months, or PR or CR for any duration Phase 1 (Dose Escalation & Backfill Cohorts) |
Screening through End of Treatment, an average of 6 months
|
|
Duration of Response (DOR)
Délai: Screening through End of Treatment or last scan, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from PR or CR to disease progression Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment or last scan, an average of 6 months
|
|
Progression Free Survival (PFS)
Délai: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from first dose to first documented date of progression per RECIST v1.1 Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
|
Overall Survival (OS)
Délai: Screening through End of Study, an average of 10 months
|
Investigate preliminary antitumor activity of BHB810 Time from first dose to death from any cause Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Study, an average of 10 months
|
|
Pharmacokinetics: Area under the concentration-time curve (AUC)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to the end of a dosing interval at steady-state (AUC0-tau)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Maximum concentration of BHB810 (Cmax) Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Time to reach maximum drug concentration of BHB810 (Tmax)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to infinity (AUC0-inf)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Terminal elimination half-life (t1/2)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Volume of drug distribution during terminal phase (Vz)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Total body clearance of the drug (CL)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to last measurable concentration sample time (AUC0-last)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Incidence of antidrug antibodies (ADAs) in blood before and after BHB810 administration
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the ADAs and PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Tumeurs par site
- Maladies intestinales
- Tumeurs par type histologique
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies de l'estomac
- Tumeurs colorectales
- Tumeurs intestinales
- Tumeurs des glandes endocrines
- Maladies pancréatiques
- Tumeurs, glandulaires et épithéliales
- Maladies du côlon
- Carcinome
- Tumeurs
- Tumeurs de l'estomac
- Tumeurs du côlon
- Tumeurs pancréatiques
- Tumeurs gastro-intestinales
- Adénocarcinome
Autres numéros d'identification d'étude
- BHB810-001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .